Merck & Co., Inc. (NYSE:MRK) Given New $140.00 Price Target at Freedom Broker

Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Freedom Broker from $125.00 to $140.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “hold” rating on the stock. Freedom Broker‘s price target would suggest a potential downside of 5.78% from the stock’s current price.

MRK has been the topic of several other reports. Jefferies Financial Group increased their price target on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. The Goldman Sachs Group upped their price target on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, August 21st. Wells Fargo & Company boosted their target price on Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, September 4th. Zacks Research lowered shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research report on Monday, October 19th. Finally, Argus boosted their target price on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Seventeen research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $155.85.

Merck & Co., Inc. Stock Down 0.6%

NYSE MRK traded down $0.94 during trading hours on Monday, reaching $148.58. 9,051,364 shares of the company’s stock were exchanged, compared to its average volume of 10,669,300. The company has a market capitalization of $366.58 billion, a price-to-earnings ratio of 153.18, a price-to-earnings-growth ratio of 6.48 and a beta of 0.21. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The company’s 50-day moving average is $146.90 and its two-hundred day moving average is $126.69.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.56%. The firm had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. During the same period in the previous year, the business earned $2.58 EPS. The company’s revenue was up 4.7% compared to the same quarter last year. On average, analysts forecast that Merck & Co., Inc. will post 2.81 EPS for the current fiscal year.

Insider Activity

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the sale, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Richard Deluca sold 20,784 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $130.43, for a total value of $2,710,857.12. Following the transaction, the executive vice president owned 134,703 shares of the company’s stock, valued at $17,569,312.29. This trade represents a 13.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MRK. Paulson Wealth Management Inc. grew its stake in Merck & Co., Inc. by 2.1% in the third quarter. Paulson Wealth Management Inc. now owns 4,875 shares of the company’s stock valued at $708,000 after acquiring an additional 100 shares during the period. Platform Technology Partners lifted its holdings in shares of Merck & Co., Inc. by 4.7% in the 3rd quarter. Platform Technology Partners now owns 14,070 shares of the company’s stock worth $2,044,000 after purchasing an additional 626 shares in the last quarter. Quest 10 Wealth Builders Inc. increased its stake in Merck & Co., Inc. by 12.2% during the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 699 shares of the company’s stock valued at $102,000 after purchasing an additional 76 shares in the last quarter. Collaborative Fund Advisors LLC raised its holdings in Merck & Co., Inc. by 80.5% during the third quarter. Collaborative Fund Advisors LLC now owns 7,802 shares of the company’s stock worth $1,134,000 after buying an additional 3,479 shares during the last quarter. Finally, Pathway Financial Advisers LLC raised its holdings in Merck & Co., Inc. by 1.6% during the third quarter. Pathway Financial Advisers LLC now owns 32,529 shares of the company’s stock worth $4,727,000 after buying an additional 518 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck will present new data from its oral HIV portfolio at HIV Glasgow 2026, including Phase 3 analyses and patient-reported outcomes for the investigational once-weekly ISL/LEN combination. Positive data could strengthen confidence in a differentiated, convenient HIV franchise. Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
• Positive Sentiment: The company is advancing oral HIV treatment and prevention regimens with once-weekly and once-monthly dosing, while the FDA has accepted supplemental applications for IDVYNSO with a decision expected in 2027. Regulatory progress provides a potential medium-term catalyst. Merck Pushes Ahead With Oral HIV Regimens And 2027 FDA Review
• Positive Sentiment: Merck’s personalized melanoma vaccine strategy is attracting investor interest because it could reduce recurrence and support long-term oncology growth beyond the company’s current portfolio. Merck stock rises as its cancer strategy gets personal
• Neutral Sentiment: Cantor Fitzgerald raised its price target from $145 to $155 but retained a Neutral rating, signaling modest upside while reflecting uncertainty around the commercial scale-up of newer launches. Merck Stocks Decline With Higher Target Leaving a New-Launch Scale Test
• Neutral Sentiment: ETF investors made approximately $22 million of net purchases on October 29, indicating institutional demand, although the flow is not a fundamental earnings catalyst. ETFs Bought $22.0 Million of Merck
• Negative Sentiment: Despite earnings beating expectations, MRK’s elevated valuation and the need to prove that new oncology and HIV products can scale are limiting enthusiasm. Analysts’ neutral positioning and reported margin headwinds are contributing to the cautious tone. MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.